



Most Texans heard something about weight loss drugs in the last 2 weeks

What they heard is generally negative

As weight loss drugs [explode in popularity](#), we asked Texans if they have heard about GLP-1 weight loss drugs like Ozempic, Wegovy, or Mounjaro in the last 2 weeks. Most (54%) said yes. This was the second highest rate among five states included in the survey.

Who is hearing about GLP-1 drugs?

Among the 551 adults surveyed in 5 states, half had heard about the weight loss drugs in the last two weeks. Women were more likely to hear about the drugs than men (52% vs. 45%), as were those living in rural vs. urban areas (62% vs. 50%).

What are they hearing?

GLP-1 medications help lower blood sugar levels for people with diabetes and also promote weight loss ([CDC](#)). However, only 25% of survey respondents who had heard about the GLP-1 drugs reported hearing how they help with chronic disease. Many more respondents heard that:

- *GLP-1 drugs have serious side effects (41%). Men were more likely to hear this than women (44% vs. 38%) as were rural vs. urban residents (59% vs. 39%).*
- *GLP-1 drugs are expensive (41%). Women more likely to hear this than men (44% vs. 29%);*
- *GLP-1 drugs are hard to get because of low supply (37%);*
- *There are fake versions of GLP-1 drugs (36%). Adults age 60+ heard this more than those under 60 (59% vs 31%), as did Black respondents vs. Whites (48% vs. 35%) and urban vs. rural residents (39% vs. 16%); and,*
- *There are issues with insurance covering GLP-1 drugs (30%). Highest, 47%, in those 60+.*

Where are they hearing it?

Among those hearing about GLP-1 drugs in the last two weeks, most (53%) heard it on

social media, especially those younger than 50 compared to 50+ (64% vs. 31%) and Hispanics vs. non-Hispanics (62% vs. 48%). News from TV, online, radio, or newspapers was the next most common source (37%), especially for adults ages 60+ vs. <60 (80% vs. 27%) and non-Hispanics vs. Hispanics (42% vs. 28%). Family or friends (also 37%) was more common among rural vs urban residents (53% vs. 35%). Other cited sources were advertisements (23%), online searches (10%), and healthcare providers (9%).

Share findings, see what others think

What do *you* think about the risks and benefits of GLP-1 drugs? Share the resources below and start a conversation. Talking openly about health issues helps with Texas response efforts.


This week's report is based on responses from a panel of 551 adult residents of Texas (n = 96), Baltimore, MD (n = 123), Colorado (n = 113), Omaha, NE (n = 82), and St. Louis, MO (n = 137) surveyed September 21-23, 2024. Explore these data and more at [iHeard Texas](#).

Shareable Resources

Click to download resources to share in your community.

Remember to include **#iHeardTexas #iHeardTX** when sharing on social media!

Weight loss drugs... what are people hearing?



WHERE are they hearing* about GLP-1 weight loss drugs?



- 1. Social media **53%**
- 2. News sources **37%**
- 3. Family or friends **37%**

Source: iHeard survey, September 21-23, 2024
*Respondents could choose more than one source.

GLP-1 drugs treat type 2 diabetes and are also used to promote weight loss.



Studies show that GLP-1 drugs work but, like any drug, can also cause side effects. It's important to weigh the risks and benefits with your doctor.

Source: CDC


Suggested Caption:

What are you hearing about GLP-1 drugs like Ozempic, Wegovy or Mounjaro? They can help lower blood sugar levels for people with type 2 diabetes and also promote weight loss.

#iHeardTexas #GLP1 #WeightLossDrugs

[Download here](#)

Weight loss drug fact sheet



[Download here](#)

Combined Resource

Click to download a printer-friendly PDF with all the information above!

[Download here](#)

Find more information on what public health topics are trending this week.

[iHeard Texas dashboard](#)

Explore past alert topics and shareable print and digital graphics in English, Spanish, and Vietnamese.

[iHeard alert library](#)



[Texas CEAL website](#)



[NIH CEAL website](#)

Was this forwarded to you?
[Sign up](#) to receive weekly alerts.

Institute for Health Disparities | 3500 Camp Bowie Blvd EAD 248E | Fort Worth, TX 76107 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!